Log In
Print this Print this

rFVIIIFc (Elocta, Eloctate)

Also known as: Long-lasting rFACTOR VIII

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionLong-acting recombinant fusion protein consisting of the Fc domain of human immunoglobulin G1 (IgG1) attached to Factor VIII
Molecular Target Factor VIII
Mechanism of ActionFactor VIII replacement
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in hemophilia A patients; Treat hemophilia A; Treat severe hemophilia A
Regulatory Designation U.S. - Orphan Drug (Treat hemophilia A);
U.S. - Undisclosed Review (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia A);
Switzerland - Orphan Drug (Treat and prevent bleeding in hemophilia A patients);
Switzerland - Orphan Drug (Treat hemophilia A)
Partner Swedish Orphan Biovitrum AB; UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today